相关实验视频
Updated: Jun 14, 2025

08:02
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
5.4K
在患有炎症性肠病的儿童中对生物药物的立即过敏反应
Sinem Polat Terece1, Hacer Ilbilge Ertoy Karagol1, Demet Teker Duztas2
1Department of Pediatric Allergy, Faculty of Medicine, Gazi University, Ankara, Turkey.
International archives of allergy and immunology
|September 4, 2024
概括
在儿科炎症性肠病 (IBD) 患者中,对生物药物 (BD) 发生即时过敏反应 (I-HSR),但通常是轻微的. 伴随性过敏性疾病增加了这些反应的风险.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 生物药物 (BD) 越来越多地用于儿科炎性肠病 (IBD).
- 这种增加可能与该人群中立即过敏反应 (I-HSR) 的发病率增加有关.
- 了解儿科IBD中的I-HSRs到BD对于患者安全和治疗优化至关重要.
研究的目的:
- 评估儿科IBD患者I-HSR到BD的频率和临床特征.
- 确定与I-HSRs发展相关的潜在风险因素.
- 评估这些反应的管理和严重程度.
主要方法:
- 一项回顾性研究包括了患有IBD的儿科IBD患者,他们经历了I-HSR到BD.
- 收集的数据范围从2006年1月1日到2023年8月1日.
- 统计分析,包括后勤回归,用于识别风险因素.
主要成果:
- 在197名儿科IBD患者中,61人使用了BD,其中6人患有I-HSR (9.8%的患者,0.36%的患者).
- 反应包括1型HSR和输液相关反应,均为轻度至中度.
- 伴随性过敏性疾病是I-HSR的一个显著风险因素 (aOR = 8.35,p = 0.029).
结论:
- 儿科IBD患者的I-HSRs到BDs并不罕见,但通常不是长期严重的.
- 伴随性过敏性疾病的存在是发展I-HSR到BD的一个关键风险因素.
- 这些发现凸显了考虑过敏病史在治疗儿科IBD患者在BD治疗中的重要性.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Hypersensitivities
559
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
559
Allergic Drug Reactions
821
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
821

